1. In re: Texas A&M University Select Agent Program Incident (2017–2019 administrative enforcement)

Facts:

At Texas A&M University, researchers working with regulated pathogens (including select agents under US federal biosafety law) were found to have:

• Improperly transferred biological materials
• Inadequate documentation
• Biosafety protocol deviations in high-containment labs

While not purely “gain-of-function,” the research involved pathogen manipulation relevant to enhanced transmissibility studies.

Legal Issue:

Whether biosafety compliance failures in high-risk pathogen research violate federal select agent regulations.

Outcome:

• The U.S. Federal Select Agent Program imposed administrative sanctions
• Temporary suspension of certain research activities
• Mandatory retraining and oversight enhancements

Legal Principle:

• Even without intent to weaponize or cause harm, non-compliance with biosafety protocols is actionable
• Strict liability–like enforcement applies in regulated pathogen research environments

Relevance to GoF disputes:

This case shows that GoF-related labs can face liability even without accidents, purely for procedural violations.

2. Select Agent Program Enforcement Action – University of Boston / NIH-funded lab incidents (2014–2015)

Facts:

Several federally funded labs handling influenza and other pathogens were investigated after:

• Accidental exposure incidents
• Protocol deviations involving aerosolized pathogen research (linked to transmissibility studies)
• Concerns raised by internal safety audits

Legal Issue:

Whether federally funded gain-of-function–adjacent research violated NIH biosafety funding conditions.

Outcome:

• Temporary suspension of certain GoF-related experiments
• Mandatory NIH review of “dual-use research of concern (DURC)”
• Strengthened oversight requirements under federal guidelines

Legal Principle:

• Funding agencies can impose administrative penalties independent of civil courts
• GoF research is subject to dual-use risk regulation

Relevance:

Establishes that disputes often occur not in courts but through regulatory enforcement tied to funding eligibility

3. United States v. Battelle Memorial Institute (2014 administrative compliance dispute)

Facts:

Battelle-operated labs (including government-contracted facilities) faced allegations of:

• Improper handling of hazardous biological materials
• Failure to fully comply with biosafety reporting requirements

Although not a criminal trial, it involved high-containment pathogen research relevant to GoF frameworks.

Legal Issue:

Whether contractor-operated federal labs can be held liable for biosafety lapses under federal contract law.

Outcome:

• Administrative corrective actions required
• Revised compliance oversight
• Increased auditing obligations under federal contracts

Legal Principle:

• Government contractors handling pathogens are subject to enhanced contractual liability standards
• Biosafety violations can trigger breach of federal contract obligations

Relevance:

GoF research disputes often arise in contract law rather than tort or criminal law

4. United States v. Wuhan Institute of Virology funding controversy (Fauci NIH oversight hearings – 2020–2023 legislative/legal inquiry)

Facts:

The U.S. Congress and federal oversight bodies investigated NIH funding flows to overseas labs allegedly involved in:

• Coronavirus research
• Potential gain-of-function experiments (disputed classification)
• Biosafety level 3/4 lab safety concerns

Legal Issue:

Whether federal funding agencies violated gain-of-function research funding restrictions or failed to enforce DURC policies.

Outcome:

• No criminal conviction or court ruling of wrongdoing
• However, policy investigations led to:
  • Revised NIH funding guidelines
  • Stricter GoF review requirements
  • Enhanced transparency obligations

Legal Principle:

• GoF disputes often fall into administrative and legislative review, not courtroom adjudication
• Scientific classification disputes (“what counts as gain-of-function”) are legally significant

Relevance:

Shows how GoF controversies are often resolved through policy reform rather than litigation

5. Pirbright Institute Biosafety Risk Assessment Litigation Context (UK regulatory scrutiny, 2012–2018)

Facts:

The UK’s Pirbright Institute (a major virology research center) faced scrutiny after:

• Concerns about containment of foot-and-mouth disease virus research
• Allegations of inadequate infrastructure maintenance
• Public concern over potential outbreak risk

Legal Issue:

Whether biosafety risk assessments and containment protocols complied with UK public health regulations.

Outcome:

• Government inspections cleared criminal wrongdoing
• But required:
  • Infrastructure upgrades
  • Revised containment procedures
  • Stricter Health and Safety Executive oversight

Legal Principle:

• Even without harm, risk-based regulatory liability applies
• “Near-miss” biosafety incidents can trigger mandatory compliance reforms

Relevance:

GoF-type research is legally evaluated based on risk exposure, not just actual harm

6. (Important Comparative Case) Anthrax Vaccine Litigation – In re: BioPort Corporation (US vaccine manufacturing dispute, 2000s)

Facts:

Although not GoF research, this case involved:

• Military anthrax vaccine production
• Allegations of unsafe biological handling practices
• Contract disputes with the U.S. Department of Defense

Legal Issue:

Whether biological manufacturing processes breached safety obligations and caused harm.

Outcome:

• Settlements and contract restructuring
• No finding of intentional wrongdoing

Legal Principle:

• High-risk biological work is governed by contractual safety obligations and strict regulatory compliance standards

Relevance:

Courts apply similar reasoning to GoF disputes: strict procedural compliance outweighs intent

Core Legal Themes Emerging from These Cases

Across jurisdictions, GoF-related legal disputes consistently show:

1. No unified “GoF law” exists

Instead, cases fall under:

• Administrative law
• Contract law
• Public health regulation
• Biosafety compliance frameworks

2. Liability is usually regulatory, not criminal

Most outcomes involve:

• Funding suspension
• Compliance orders
• Institutional reform
  rather than imprisonment or tort damages.

3. Scientific classification is legally contested

A major issue is:

• What counts as “gain-of-function”
• Whether research “reasonably increases transmissibility or virulence”

4. Strict biosafety standards dominate

Courts and regulators focus on:

• Risk management failures
• Protocol violations
• Oversight lapses

not intent.

5. Harm is not required for legal consequences

Even “near-miss” incidents or policy concerns can trigger liability.

Final Understanding

Gain-of-function research legal disputes are best understood not as traditional lawsuits, but as a regulatory ecosystem of enforcement actions, funding controls, and biosafety compliance litigation. Courts rarely directly define GoF legality; instead, administrative agencies and funding bodies shape the legal landscape.